Table 2 Changes after SARS-CoV-2 infection in MHD patients
Before SARS-CoV-2 infection | During SARS-CoV-2 infection | After SARS-CoV-2 infection one month | P | |
|---|---|---|---|---|
Monthly averaged pre-HD systolic BP (mmHg, mean ± SD) | 151.4 ± 15.4 | 152.5 ± 16.0 | 150.4 ± 17.1 | 0.3 |
Monthly averaged pre-HD diastolic BP (mmHg, mean ± SD) | 78.4 ± 11.6 | 79.3 ± 12.5 | 78.6 ± 11.7 | 0.5 |
KT/V (median and IQR) | 1.5(1.4,1.7) | 1.5(1.3,1.7) | 1.5(1.4,1.7) | 0.9 |
Weekly averaged EPO dose (IU, median and IQR) | 7500(6000,9000) | 9000(6000,12000) | 9000(6000,12000) | 0.053 |
Hemoglobin (g/L, median and IQR) | 113.0(108.0,120.0) | 111.0(106.0,118.0) | 107.0(99.0,115.0) | 0.0001 |
Albumin (g/L, mean ± SD) | 39.4 ± 3.2 | 36.1 ± 3.4 | 38.5 ± 4.5 | < 0.0001 |
Potassium (mmol/L, mean ± SD) | 4.8 ± 0.7 | 4.4 ± 0.6 | 4.6 ± 0.6 | < 0.0001 |
Sodium (mmol/L, mean ± SD) | 136.5 ± 2.9 | 135.5 ± 3.6 | 135.5 ± 3.7 | 0.0007 |
Ferritin (ng/L, median and IQR) | 257.7(171.0,361.8) | 537.0(340.2,814.6) | - | < 0.0001 |
Serum iron (umol/L, median and IQR) | 10.3(8.9,12.9) | 9.4(6.7,12.9) | - | 0.02 |
Leukocyte (10^9/l, median and IQR) | 6.2(4.8,7.0) | 5.5(4.3,6.8) | 6.3(4.9,7.9) | 0.035 |
Lymphocyte (10^9/l, median and IQR) | 1.1(0.8,1.4) | 0.9(0.7,1.2) | 1.1(0.8,1.3) | 0.052 |
C-reactive protein (mg/l, median and IQR) | 2.9(1.6,9.1) | 11.8(3.3,43.7) | 5.6(2.6,14.7) | < 0.0001 |
Predialysis Weight (kg, median and IQR) | 67.7(57.6,77.3) | 66.2(56.9,77.0) | 66.1(56.9,77.2) | 0.9 |